Neutra Corp. (OTCBB: NTRR), an emerging nutraceuticals provider, expects
to begin clinical trials of its eagerly anticipated new all-natural
weight-loss supplement as early as this week when the company’s first
batch of Pure Plus arrives from the manufacturer.
NTRR is currently in the midst of recruiting and qualifying suitable
volunteers in order to begin testing as soon as the supplements are
delivered. The initial test batch as well as each subsequent shipment of
Pure Plus is first sent from the manufacturer to a laboratory for a
highly specialized Bio-energy infusion that increases the potency of the
ingredients, before the supplements’ final delivery to the company.
Beginning clinical trials on the all-natural fat-burner is an exciting,
major step forward for the company. Pure Plus will be the
first in a product line of superior, all-natural supplements that Neutra
Corp. is working to bring to retail shelves as quickly as possible. The
breakthrough Bio-energy infusion proven to significantly enhance the
supplement’s performance will be the hallmark that sets Pure Plus apart
from its competitors.
NTRR expects to announce the results of the trial testing within 30 days
of completion.
Neutra Corp. is developing Pure Plus and other new products to compete
in the fast-growing nutraceuticals industry alongside Herbalife Ltd.
(NYSE: HLF), Nature's Sunshine Prod. (NASDAQ: NATR), Nutraceutical
International Corp. (NASDAQ: NUTR) and Schiff Nutrition International
Inc. (NYSE: WNI).
For more information on NTRR’s nutraceuticals initiative, please visit www.neutracorp.com/investors.
Follow NTRR on Twitter at www.twitter.com/neutracorp.
About Neutra Corp.
Neutra Corp. ()
is a healthy lifestyle company that specializes in the development and
marketing of nutritional supplements, nutrient boosters, herbal remedies
and other natural wellness solutions. The company is currently working
to produce a full range of products to address every component of a
healthy lifestyle, including muscle building, weight loss and general
wellness through a daily nutrition regimen. For investing information
and performance data, please visit .
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.

Add GEN to your Inbox FREE!
Subscribe today to our complimentary e-Newsletters and stay abreast of the latest biotech news and trends.